A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481

Blood

Volumn 107, Issue 12, 2006, Pages 4606-4613

  Massey, Gita V ^a   Zipursky, Alvin ^a   Chang, Myron N ^a   Doyle, John J ^a   Nasim, Suhail ^a   Taub, Jeffrey W ^a   Ravindranath, Yaddanapudi ^a   Dahl, Gary ^a   Weinstein, Howard J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIBODY; BILIRUBIN; CD20 ANTIBODY; CD3 ANTIBODY; LIVER ENZYME; T LYMPHOCYTE ANTIBODY; THROMBOCYTE ANTIBODY;

ARTICLE; BIOLOGICAL TRAIT; BLAST CELL; BLOOD CELL COUNT; CELL COUNT; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLONAL VARIATION; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; DOWN SYNDROME; FEMALE; FLUOROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; LABORATORY TEST; LEUKEMIA; LIVER BIOPSY; MALE; MORPHOLOGY; MOSAICISM; NEWBORN; NEWBORN MORTALITY; ONCOLOGY WARD; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; TRISOMY;

EID: 33745076542     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2448     Document Type: Article

References (58)

1. Zipursky A, Rose T, Skidmore M, et al. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol. 1996;13:81-87.
2. Broadbent VA. Malignant disease in the neonate. In: Roberton NRC, ed. Textbook of Neonatology, ed. 2. Edinburgh, United Kingdom: Churchill Livingstone; 1992:879.
3. Robison LL, Nesbit ME, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. J Pediatr. 1984;105:235-242.
4. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139-149.
5. Zipursky A, Brown E, Christensen H, et al. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21:97-101.
6. Schunk GJ, Lehman WL. Mongolism and congenital leukemia. JAMA. 1954;155:250-251.
7. Weinstein HJ. Congenital leukemia and the neonatal myeloproliferative disorders associated with Down syndrome: a report. Clin Haematol. 1978;7:147-154.
8. Wong KY, Jones MM, Svrivastava AK, et al. Transient myeloproliferative disorder and acute nonlymphoblastic leukemia in Down syndrome. J Pediatr. 1988;112:18-22.
9. Paolucci G, Rosito P. Neonatal myeloproliferative disorders in Down syndrome and congenital leukemias. Haematologica. 1987;72:121-125.
10. Nakagawa T, Nishida H, Arai T, et al. Hyperviscosity syndrome with transient abnormal myelopoiesis in Down syndrome. J Pediatr. 1988;112:58-61.
11. Becroft DMO, Zwi LJ. Perinatal visceral fibrosis accompanying the megakaryoblastic leukemoid reaction to Down syndrome. Pediatr Pathol. 1990;10:397-406.
12. Ruchelli ED, Uri A, Dimmick JE, et al. Severe perinatal liver disease and Down syndrome: an apparent relationship. Hum Pathol. 1991;22:1274-1280.
13. Miyauchi J, Ito Y, Kawano, T, et al. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood. 1992;80:1521-1527.
14. Foucar K, Friedman K, Llewellyn A, et al. Prenatal diagnosis of transient myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down syndrome. Am J Clin Pathol. 1992;97:584-590.
15. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15:392-399.
16. Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2002;24:9-13.
17. Issacs H. Fetal and neonatal leukemia. J Pediatr Hematol Oncol. 2003;25:348-361.
18. Barnett PL, Clark AC, Garson OM. Acute nonlymphocytic after transient myeloproliferative disorder in a patient with Down syndrome. Med Pediatr Oncol. 1990;18:347-353.
19. Doyle JJ, Thorner P, Poon A, et al. Transient leukemia followed by megakaryoblastic leukemia in a child with mosaic Down syndrome. Leuk Lymphoma. 1995;17:345-350.
20. Alman BA, Pajerski ME, Diaz-Cano S, et al. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997;6:98-101.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;35:457-481.
22. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
23. Cox DR. Regression models and life-tables. J Royal Stat Soc. 1972;34:187-220.
24. Zipursky A, Christensen H, De Harven E. Ultrastructural studies of megakaryoblastic leukemias of Down syndrome. Leuk Lymphoma. 1995;18:341-347.
25. Zipursky A, Brown EJ, Christensen H, et al. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations. Clin Lab Med. 1999;19:157-167.
26. Yumura-Yagi K, Hara J, Kurahashi H, et al. Mixed phenotype of blasts in acute megakaryocytic leukemia and transient abnormal myelopoiesis in Down syndrome. Br J Haematol. 1992;81:520-525.
27. Worth L, Zipursky A, Christensen H, et al. Transient leukemia with extreme basophilia in a phenotypically normal infant with blast cells containing a pseudodiploid clone, 46, XY I(21(q10)). J Pediatr Hematol Oncol. 1999;21:63-66.
28. Suda T, Suda J, Miura Y, et al. Clonal analysis of basophil differentiation in bone marrow cultures from a Down syndrome patient with megakaryoblastic leukemia. Blood. 1985;66:1278-1283.
29. Ito E, Kasai M, Hayashi Y, et al. Expression of erythroid specific genes in acute megakaryoblastic leukemia and transient myeloproliferative disorder in Down syndrome. Br J Haematol. 1995;90:607-614.
30. Kurahashi H, Hara J, Yumura-Yagi K, et al. Monoclonal nature of transient abnormal myelopoiesis in Down syndrome. Blood. 1991;77:1161-1163.
31. Miyashita T, Asada M, Fujimoto J, et al. Clonal analysis of transient myeloproliferative disorder in Down syndrome. Leukemia. 1991;5:56-59.
32. Baschat AA, Wagner T, Malisius R, et al. Prenatal diagnosis of a transient myeloproliferative disorder in trisomy 21. Prenat Diagn. 1998;18:731-736.
33. de Tar MW, Dittman W, Gilbert J. Transient myeloproliferative disease of the newborn: case report with placental, cytogenetic and flow cytometric findings. Hum Pathol. 2000;31:396-398.
34. Donnenfeld AE, Scott SC, Henselder-Kimmel M, et al. Prenatally diagnosed non-immune hydrops caused by congenital transient leukemia. Prenat Diagn. 1994;14:721-724.
35. Hendricks S, Sorensen T T, Baker E. Trisomy 21, fetal hydrops and anemia: prenatal diagnosis of transient myeloproliferative disorder. Obstet Gynecol. 1993;82:703-705.
36. Yagihashi N, Watanabe K, Yagihashi S. Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome. J Clin Pathol. 1995;48:973-975.
37. Ravindranath Y, Abella E, Krischer J, et al. Acute myeloid leukemia (AML) in Down syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology AML study 8498. Blood. 1992;80:2210-2214.
38. Lange B, Kobrinsky N, Barnard D, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood. 1998;91:608-615.
39. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome. Leukemia. 2000;14:786-791.
40. Doyle JJ, Zipursky A. Down syndrome children with neonatal transient leukemia. Survival and risk of subsequent myelodysplasia and leukemia [abstract]. Blood. 1994;84:316a.
41. Kwong YL, Cheng G, Tang TS, et al. Transient myeloproliferative disorder in a Down's neonate with rearranged T-cell receptor beta gene and evidence of in vivo maturation demonstrated by dual-colour flow cytometric DNA ploidy analysis. Leukemia. 1993;7:1667-1671.
42. Tsuboi K, Yazaki M, Miwa H, et al. Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndrome. Int J Hematol. 2002;76:69-73.
43. Cavani S, Perfumo C, Argusti A, et al. Cytogenetic and molecular study of 32 Down syndrome families: potential leukaemia predisposing role of the most proximal segment of chromosome 21q. Br J Haematol. 1998;103:213-216.
44. Abe K, Kajii T, Niikawa N. Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative disorder. Hum Genet. 1989;82:213-216.
45. Lorber BJ, Freeman SB, Hassold T, et al. Characterization and molecular analysis of nondisjunction in 18 cases of trisomy 21 and leukemia. Genes Chromosomes Cancer. 1992;4:222-227.
46. Shea J, Williams B, Zipursky A, et al. Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am J Hum Genet. 1995;56:915-925.
47. Ho C, Otterud B, Legare R, et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood. 1996;87:5218-5224.
48. Okuda T, van Deursen J, Hiebert S, et al. AML 1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
49. Breton-Gorius J, Bizet M, Reyes F, et al. Myelofibrosis and acute megakaryoblastic leukemia in a child: topographic relationship between fibroblasts and megakaryocytes with alpha granule defect. Leuk Res. 1982;6:97-110.
50. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor beta in acute megakaryoblastic leukemia and its possible implication in myelofibrosis. Blood. 1990;75:1540-1548.
51. Martin D, Zon L, Mutter G et al. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature. 1990;344:444-447.
52. Romeo P, Prandini M, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature. 1990;344:447-449.
53. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
54. Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300.
55. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101:4301-4304.
56. Taub J, Mundschau G, Ge Y, et al. Prenatal origin of GATA 1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004;104:1588-1589.
57. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393-1400.
58. Taub JW, Huang X, Ge Y, et al. Cystathione-beta-synthase cDNA transfection alters the sensitivity of metabolism of 1-beta-D-arabino- furanosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Cancer Res. 2000;60:6421-6426.